Quarterly report pursuant to Section 13 or 15(d)

REVENUES

v3.23.3
REVENUES
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
REVENUES

NOTE 9 – REVENUES

 

Disaggregation of Net Revenues

 

The Company’s net product revenues are summarized below:

 

                         
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2023     2022     2023     2022  
Zembrace® Symtouch®   $ 3,292     $ —     $ 3,292     $ —  
Tosymra®     697     $ —     $ 697     $ —  
Total product revenues   $ 3,989     $ —     $ 3,989     $ —  

 

Gross-to-Net Sales Accruals

 

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

 

Our provision for gross-to-net allowances was $2.5 million at September 30, 2023, $0.7 million of which was recorded as a reduction to accounts receivable and $1.8 million recorded as a component of accrued expenses.